
Amgen Inc.
AMGNHealthcare|Drug Manufacturers - General|US
$460.42
+0.14 (+0.03%)
DCF Value
$902.10
Graham Number
$101.79
Cash / Share
$24.38
Next Earnings Report
Feb 2, 2027
EPS est. $5.65 · Revenue est. $10.45B
Financing Filings (last 12 months)
3
Shelf registrations / offering prospectuses — latest Feb 19, 2026 (424B2). Possible dilution.
Upcoming Data Readouts (51)
Dec 2026
Est. completion
P1NF1
Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1
NCT07102394n=10
Dec 2026
Est. completion
P1P2Acute Lymphoblastic Leukemia
A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance
NCT03114865n=44
Jan 2027
Est. completion
P1P2Thyroid Eye Disease
A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease
NCT06401044n=94
Jan 2027
Est. completion
P1Healthy Participants
Comparing the Extent to Which Romosozumab (AMG 785) is Made Available in the Body When Administered as a Single SC Injection or as 2 SC Injections
NCT07811999n=308
Jan 2027
Est. completion
P3Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
NCT06858878n=1,105
Feb 2027
Est. completion
Heart Failure NYHA Class II
Early Metabolic Adaptations to SGLT2 Inhibition in Heart Failure
NCT05885607n=40
Mar 2027
Est. completion
Mar 2027
Est. completion
P1Healthy Participants
A Phase 1 Trial of AMG 691 in Healthy Chinese and Japanese Volunteers
NCT07745907n=28
May 2027
Est. completion
Jun 2027
Est. completion
NACardiovascular Risk
Impact of the Corrie Lipids Digital Health Program on Lipid Optimization
NCT07478887n=1,000
Jun 2027
Est. completion
P3Secondary Hyperparathyroidism
A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis
NCT03969329n=24
Jun 2027
Est. completion
P3Non-Small Cell Lung Cancer (NSCLC)
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
NCT05920356n=750
Jul 2027
Est. completion
Jul 2027
Est. completion
P3Vasculitis
Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV.
NCT06321601n=19
Aug 2027
Est. completion
P3Obesity
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy
NCT07225686n=250
Aug 2027
Est. completion
P2Overweight or Obesity and Elevated Liver Fat
A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight
NCT07441252n=180
Sep 2027
Est. completion
Sep 2027
Est. completion
P2Metastatic Gastro-esophageal Adenocarcinoma
Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy
NCT06680622n=126
Sep 2027
Est. completion
P3Small Cell Lung Cancer
Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)
NCT07778316n=400
Dec 2027
Est. completion
P3Obesity
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
NCT07684235n=3,200
Awaiting Results (10)
Trials past primary completion date but still active — data readout may be imminent.
Nov 2026
P1
A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes Mellitus
NCT07160257Oct 2026
P2
A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
NCT06593522Jun 2026
P1P2
Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients
NCT05074810Jun 2026
P2
Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma
NCT03500445May 2026
P4
Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction Upbound to PCI
NCT04951856Dec 2025
P3
A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease
NCT06248619Sep 2023
P2
Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant
NCT03289299Jul 2018
P2
Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma
NCT02415413Recent Press Releases
REPATHA® LOWERS RISK OF HEART ATTACKS BY 20% COMPARED WITH EZETIMIBE IN A LARGE REAL-WORLD STUDY
Nov 5, 2026 · PRNewsWire
AMGEN REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS
Nov 3, 2026 · PRNewsWire
AMGEN ANNOUNCES WEBCAST OF 2026 THIRD QUARTER FINANCIAL RESULTS
Oct 28, 2026 · PRNewsWire
AMGEN TO PRESENT NEW DATA ACROSS RARE AND OTHER SERIOUS AUTOIMMUNE DISEASES AT ACR CONVERGENCE 2026
Oct 27, 2026 · PRNewsWire
AMGEN APPOINTS DAVID W. GIBBS TO BOARD OF DIRECTORS
Oct 26, 2026 · PRNewsWire
IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
Oct 24, 2026 · PRNewsWire
AMGEN TO PRESENT AT THE EUROPEAN SOCIETY OF MEDICAL ONCOLOGY CONGRESS 2026
Oct 20, 2026 · PRNewsWire
TEZSPIRE® DELIVERED HISTOLOGIC REMISSION AND SYMPTOM IMPROVEMENT IN EOSINOPHILIC ESOPHAGITIS
Oct 20, 2026 · PRNewsWire
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE
Sep 22, 2026 · PRNewsWire
FDA APPROVES REDUCED MONITORING TIME FOR FIRST TWO DOSES OF IMDELLTRA®
Sep 14, 2026 · PRNewsWire
SEC Filings (48)
Last two years from EDGAR. Insider Form 4s are on the Ownership tab.
| Filed | Form | What it is | Links |
|---|---|---|---|
| Nov 4, 2026 | 10-Q | Quarterly report | DocumentIndex |
| Nov 3, 2026 | 8-K | Material event | DocumentIndex |
| Oct 27, 2026 | 8-K | Material event | DocumentIndex |
| Aug 5, 2026 | 10-Q | Quarterly report | DocumentIndex |
| Aug 4, 2026 | 8-K | Material event | DocumentIndex |
| Jul 31, 2026 | 8-K | Material event | DocumentIndex |
| Jun 11, 2026 | 11-K | DocumentIndex | |
| Jun 11, 2026 | 11-K | DocumentIndex | |
| May 20, 2026 | 8-K | Material event | DocumentIndex |
| May 19, 2026 | 8-K | Material event | DocumentIndex |
| May 14, 2026 | SC 13G | Passive 5%+ stake | DocumentIndex |
| Apr 30, 2026 | 8-K | Material event | DocumentIndex |
| Apr 29, 2026 | SC 13G | Passive 5%+ stake | DocumentIndex |
| Apr 22, 2026 | 8-K | Material event | DocumentIndex |
| Apr 21, 2026 | DEFA14A | Proxy / shareholder vote | DocumentIndex |
| Apr 15, 2026 | DEFA14A | Proxy / shareholder vote | DocumentIndex |
| Apr 7, 2026 | DEFA14A | Proxy / shareholder vote | DocumentIndex |
| Apr 7, 2026 | DEF 14A | Proxy / shareholder vote | DocumentIndex |
| Mar 31, 2026 | ARS | Annual report to holders | DocumentIndex |
| Mar 26, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Feb 24, 2026 | 25-NSE | DocumentIndex | |
| Feb 19, 2026 | 8-K | Material event | DocumentIndex |
| Feb 19, 2026 | 424B2 | Offering prospectus | DocumentIndex |
| Feb 17, 2026 | FWP | DocumentIndex | |
| Feb 17, 2026 | 424B3 | Offering prospectus | DocumentIndex |
| Feb 13, 2026 | S-3ASR | Shelf registration | DocumentIndex |
| Feb 13, 2026 | 10-K | Annual report | DocumentIndex |
| Feb 3, 2026 | 8-K | Material event | DocumentIndex |
| Jan 30, 2026 | 8-K | Material event | DocumentIndex |
| Nov 5, 2025 | 10-Q | Quarterly report | DocumentIndex |
| Nov 4, 2025 | 8-K | Material event | DocumentIndex |
| Sep 8, 2025 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Aug 6, 2025 | 10-Q | Quarterly report | DocumentIndex |
| Aug 5, 2025 | 8-K | Material event | DocumentIndex |
| Jun 12, 2025 | 11-K | DocumentIndex | |
| Jun 12, 2025 | 11-K | DocumentIndex | |
| May 27, 2025 | 8-K | Material event | DocumentIndex |
| May 2, 2025 | 10-Q | Quarterly report | DocumentIndex |
| May 1, 2025 | 8-K | Material event | DocumentIndex |
| Apr 29, 2025 | DEFA14A | Proxy / shareholder vote | DocumentIndex |